Bioxyne Limited has announced that it has appointed specialist biotechnology investment banking advisors Torreya Partners LLC as investment bankers to facilitate the commercialization of the lead HI 164 OV product.
Torreya Partners will work with Bioxyne management to provide support during the commercialization process.
This will include, facilitating and advising on negotiations with a range of potential strategic partners to license, sell or partner Bioxyne’s new therapy for chronic obstructive pulmonary disease (COPD).
In June, Bioxyne is scheduled to release data from the Phase IIb trial aimed at establishing the safety and efficacy of its new therapy, HI-164OV, for the medical needs of chronic COPD patients.
Bioxyne Chief Executive Officer David Radford said, "There is growing interest among the respiratory medical community and pharmaceutical industry in the release of the Phase IIb data from our trial and a recognition of the potential future value of an effective new therapy that could help address the medical needs of COPD patients worldwide.
“Bioxyne is engaged with a growing number of potential strategic corporate partners in multiple geographies. Torreya Partners will help us manage this important process in a timely and efficient manner to achieve the best long term results and create shareholder value,” Mr Radford said.